Japan Tissue Engineering: Overview of Q1 2025 earnings report.
Japan Tissue Engineering: The skin sensitization test method, "EpiSensA," which uses the human 3D-cultured epidermal model "Labosite Epi-Model 24," has been standardized worldwide.
Japan Tissue Engineering: Aichi Prefecture cooperates with 'Science Practicum Experience Research Labs' - high school students in the prefecture experience cutting-edge science and technology at universities and companies.
Japan Tissue Engineering: Regarding matters related to dominant shareholders.
Japan Tissue Engineering: Announcements of organizational changes and personnel changes
Japan Tissue Engineering: Submission of an application for approval of partial changes to in-house cultivated cartilage (JACC).
Japan Tissue Engineering: Submission of part modification approval application for autologous cultured cartilage "Jack" towards expanded indication for osteoarthritis of the knee joint.
Japan Tissue Engineering: Ritsumeikan University has signed an agreement regarding cooperation with the Faculty of Pharmacy – promoting the development of next-generation personnel in regenerative medicine and deepening industry-academia exchanges.
Japan Tissue Engineering: Announcements of individual stocks: Notice of adoption of New Aichi Creation Research and Development Grant in 2024.
Japan Tissue Engineering: Matters relating to business plans and growth potential
Japan Tissue Engineering: 2024 financial results overview
Japan Tissue Engineering: A special letter of appreciation was received at the ceremony commemorating the 70th anniversary of the enforcement of the Gamagori city system -- Contribution to the “town of regenerative medicine, Gamagori” --
Japan Tissue Engineering: Announcement of receiving 2 excellent abstract awards at the 23rd Annual Meeting of the Japanese Society for Regenerative Medicine ~Our basic research efforts on mesenchymal stem cells~
Japan Tissue Engineering: Notice Concerning Selection of Lending Stocks for Our Shares
Japan Tissue Engineering: Autologous Cultured Cartilage Jack: Notice Concerning Insurance Reimbursement Price Revision
Japan Tissue Engineering: Autologous Cultured Cartilage Jack: Notice on the progress of clinical trials aimed at expanding adaptation to knee osteoarthritis
Japan Tissue Engineering: Notice of obtaining a Class 1 medical device manufacturing and sales license and medical device manufacturing registration for the market of other (same type) dried human cultured epidermis
Japan Tissue Engineering: Summary of Financial Results for the third quarter 2024
Japan Tissue Engineering: Regenerative Medicine for the Knee using Autologous Cultured Cartilage: Application all over Japan - a track record of usage in all 47 prefectures
Japan Tissue Engineering: Knee regenerative medicine using autologous cultured cartilage is familiar and has been used all over Japan and has a track record of use in all 47 prefectures
No Data